Inhibitors of dipeptidyl-aminopeptidase type IV

Details Inhibitors of dipeptidyl-aminopeptidase type IV Inhibitors of dipeptidyl-aminopeptidase type IV

2007-06-12

2007-06-12

Lukton, David (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

4 to 5 amino acid residues in defined sequence

C530S327000, C530S328000, C530S329000, C530S331000, C568S001000, C548S535000, C514S015800, C514S016700, C514S017400, C514S018700

Reexamination Certificate

active

10775598

ABSTRACT:
Peptide inhibitors of dipeptidyl-aminopeptidase type IV (DP-IV) are provided. The peptide inhibitors have an isomeric purity of about 96–99 percent. The peptide inhibitors include one or more amino acids covalently coupled to boroproline moiety. The compounds are useful as DP-IV inhibitors, in vivo and in vitro.

REFERENCES:
patent: 4318904 (1982-03-01), Shaw et al.
patent: 4443609 (1984-04-01), Oude Alink et al.
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4582821 (1986-04-01), Kettner et al.
patent: 4636492 (1987-01-01), Kettner et al.
patent: 4644055 (1987-02-01), Kettner et al.
patent: 4652552 (1987-03-01), Kettner et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5093477 (1992-03-01), Molling et al.
patent: 5183653 (1993-02-01), Linder et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5215926 (1993-06-01), Etchells, III et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250720 (1993-10-01), Kettner et al.
patent: 5288707 (1994-02-01), Metternich
patent: 5296604 (1994-03-01), Hanko et al.
patent: 5378624 (1995-01-01), Berenson et al.
patent: 5384410 (1995-01-01), Kettner
patent: 5444049 (1995-08-01), de Nanteuil et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5506130 (1996-04-01), Peterson et al.
patent: 5527923 (1996-06-01), Klingler et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5635386 (1997-06-01), Palsson et al.
patent: 5646043 (1997-07-01), Emerson et al.
patent: 5965532 (1999-10-01), Bachovchin
patent: 6040145 (2000-03-01), Huber et al.
patent: 6100234 (2000-08-01), Huber et al.
patent: 6503882 (2003-01-01), Huber et al.
patent: 6692753 (2004-02-01), Huber et al.
patent: 6825169 (2004-11-01), Bachovchin et al.
patent: 6875737 (2005-04-01), Bachovchin
patent: 0 356 223 (1990-02-01), None
patent: 0 371 467 (1990-06-01), None
patent: 0 471651 (1992-02-01), None
patent: 0 481 311 (1992-04-01), None
patent: 0 615 978 (1994-09-01), None
patent: 0 420 913 (1995-11-01), None
patent: 0 688 788 (1995-12-01), None
patent: 0 528 858 (1997-01-01), None
patent: WO-89/03223 (1989-04-01), None
patent: WO-91/16339 (1991-10-01), None
patent: WO-91/17767 (1991-11-01), None
patent: WO-92/12140 (1992-07-01), None
patent: WO-92/17490 (1992-10-01), None
patent: WO-93/02057 (1993-02-01), None
patent: WO-93/05011 (1993-03-01), None
patent: WO-93/08259 (1993-04-01), None
patent: WO-93/10127 (1993-05-01), None
patent: WO-93/16102 (1993-08-01), None
patent: WO-94/03055 (1994-02-01), None
patent: WO-94/09132 (1994-04-01), None
patent: WO-94/20526 (1994-09-01), None
patent: WO-94/25873 (1994-11-01), None
patent: WO-94/28915 (1994-12-01), None
patent: WO-94/29335 (1994-12-01), None
patent: WO-95/11689 (1995-05-01), None
patent: WO-95/12618 (1995-05-01), None
patent: WO-95/15309 (1995-06-01), None
patent: WO-95/29190 (1995-11-01), None
patent: WO-95/29691 (1995-11-01), None
patent: WO-95/34538 (1995-12-01), None
patent: WO-96/40263 (1996-12-01), None
patent: WO-96/40858 (1996-12-01), None
patent: WO-98/50046 (1998-11-01), None
patent: WO-98/50066 (1998-11-01), None
Aguila, et al., “From stem cells to lymphocytes: Biology and transplantation”,Immun Rev,157: 13-40, 1997.
Austin, et al., “Proximity versus Allostery: The Role of regulated protein dimerization in biology”,Chemistry & Biology,1: 131-36, 1994.
Bachovchin, et al., “Inhibition of IGA1 proteinases from neisseria gonorrhoeae and hemophilus influenzae by peptide prolyl boronic acids”,J Biol Chem,265: 3738-43, 1990.
Bailey, “An introduction to peptide chemistry”,Wiley.,1-81, 1990. (Tables of Contents).
Barton, et al., “Binding of the T Cell activation monoclonal antibody tal to dipeptidyl”,J. of Leukocyte Biology,48: 291-96, 1990. (Abstract only).
Baugh, et al., “Proteinases and tumor invasion”, 165: 157-179, 1980.
Bodansky, “Peptide Chemistry, A Practical Textbook”,Springer-Verlag,1-9, 1988.
Bodansky, “Principles of Peptide Synthesis”,Springer-Verlag,16, 1984. (Cover page, title pages, vol. 16 cover page and pp. VII-XIII only).
Bodansky, “Principles of Peptide Synthesis”,Springer-Verlag,21, 1984.
Boros, et al., “Fluoroolefin peptide isosteres-tools for controlling peptide conformations”,Tetrahedron Letters,35: 6033-36, 1994.
Bough, et al., “Role and potential therapeutic value of proteinase inhibitors in tissue destruction”, Raven Press NY, 157-80, 1980. (ISBN 0-89004-515-1).
Brady, et al., “Reflections on a peptide”,Nature,368: 692-3, 1994.
Brander, et al.,J. of Immunol.,155(5): 2670-78, 1995. (Abstract only).
Brenchley, et al.,Nephrology, Dialysis, Transplantation,7 Suppl(1): 121, 1992.
Bristol, et al., “Characterization of a novel rat thymocyte costimulating monoclonal antibody 1.3”,J. of Immunol., 148: 332-38. 1992. (Abstract only).
Bristol, et al., “Thymocyte costimulating antigen is CD26 (dipeptidyl-granulocyte, marcrophage, t lineage cell proliferation via CD26”,J. of Immunol., 149: 367-72, 1992. (Abstract only).
Bungy, et al.,Eur. J. of Immunol., 24(9): 2098-2103, 1994. (Abstract only).
Chan, et al.,Archives of Opthalmology, 113(5): 597-600, 1995. (Abstract only).
Chazenblak, et al.,J. of Clinical Investigation, 92(1):62-74, 1993. (Abstract only).
Colowich, et al., “Methods in Enzymology”, pp. 220-225.
Cordes, et al., “Transition states for hydrolysis of acetals, ketals, glycosides and glycosylamines”,Transition States of Biochemical Processes, Plenum Press, Ch. II: 429-66, 1978. (ISBN 0-306-31092-9).
Coutts, et al., “Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV.1. Variation of the P2 position of X22-boroPro dipeptides”,J. Med. Chem., 39: 2087-94, 1996.
Dang, et al., “Cell surface modulation of CD26 by anti-1F7 monoclonal antibody: analysis surface expression and human T cell activation”,J. of Immunol., 145: 3963-71, 1990. (Abstract only).
Darcy, et al.,J. of Immunol., 149(11): 3636-3641, 1992. (Abstract only).
Darmoul, et al., “Dipeptidyl Peptidase IV (CD26) Gene Expression in enterocyte-like colon lines HT-29 and Caco-2: Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation”,J. of Biological Chemistry, 267: 2200-08, 1992.
Daw, et al.,J. of Immunol., 156(2): 818-25, 1996. (Abstract only).
De Caestecker, et al., “The detection of intercytoplasmic interleukin 1 (alpha) expression monocytes using two colour immunofluorescence flow cytometry”,J. Immunol. Methods,154: 11-20, 1992.
“Dependent on the expression of the T cell receptor/CD3 complex”,J. of Immunol.,141: 1103. (Abstract only).
Demuth, et al., “Design of (Omega-N-(O-ACYL)Hydroxy Amid) Aminodicarboxylic acid pyrrolidides as potent inhibitors of praline-specific peptidases”,FEBS Lett,320: 23-27, 1993.
Dudler, et al.,Eur. J. of Immunol.,25(2): 538-542, 1995. (Abstract only).
Duke-Cohn, et al., “Targeting of an activated T-Cell subset using a bispecific toxin conjugat directed against CD4 and CD26”,Blood,82(7): 2224-2234, 1993. (Abstract only).
DuPont, “Immunology of hematopoietic stem cell transplantation: A brief review of its history”,Immun Rev,157: 5-12, 1997.
Ebenbichler, et al., “Structure-function relationships of the HIV-1 envelope V3 determinant: evidence for two distinct conformations”,Acids,7: 639-46, 1993.
El Far, et al.,J. of Neurochemistry,64(4): 1696-1702, 1995.
Fauci, et al., “The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis”,Science,239: 617:722, 1988. (Abstract only).
Fleischer, et al., “Triggering of Cytotoxic T Lymphocytes and NK Cells via the Tp103 Pathway is dependents on the expression of the T Cell receptor/ CD3 complex”, J. of Immunol., 141: 1103-07. (Abstract).
Flentke, et al., “

Affiliated with

Also associated with

Rating

Inhibitors of dipeptidyl-aminopeptidase type IV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of dipeptidyl-aminopeptidase type IV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of dipeptidyl-aminopeptidase type IV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3807150